- Health at Bayer
-
Pharmaceuticals
- Treatment Areas
- Innovation & Technologies
- Cell and Gene Therapy
-
Sustainability
- Patient Access Charter
- Leadership Perspective
- Strengthening Healthcare Access
- Moving Non-Communicable Diseases Care Forward
- Ensuring a Sustainable Product Supply
- Delivering Better Cancer Care
-
Empowering Women, Globally
- Boosting Family Planning Usage through Digital Channels
- Capacity building: Addressing Root Causes through Partnerships
- Impact at Scale: The Challenge Initiative
- Promoting Awareness: World Contraception Day (WCD) & the Your Life Campaign
- Providing Accessible and Affordable Contraceptives
- Enabling Family Planning in Humanitarian Settings
- Fighting Neglected Tropical Diseases
- Transparency
- News & Stories
- Personal Health
- Report a Side Effect
- Medical Counterfeits
Activating the immune response: Tumor cells can evade the detection and elimination of the body’s immune system. Immuno-oncology (IO) aims to activate the immune system to find and kill tumor cells. We are developing next-generation IO approaches that interfere at various stages of the cancer immune cycle to support the patient’s immune system, helping it fight the cancer from the inside.
We are currently advancing a series of small molecule and antibody programs through preclinical and early clinical development addressing different IO targets.
In 2013, the German Cancer Research Center (DKFZ) and Bayer extended their successful strategic research alliance in search of novel cancer therapeutics by a new focus on immune-oncology and a joint laboratory to advance IO treatment options and to improve patient lives.